- AmbioPharm will complete its Shanghai Building 2 expansion next month, adding 75,000 sq. ft. of manufacturing space.
- The site will support GMP peptide API production at scales up to 50–100 kgs.
AmbioPharm, a global peptide contract development and manufacturing organisation (CDMO), is set to complete the expansion of its Shanghai Building 2 facility next month. The project will add nearly 75,000 square feet of commercial-scale manufacturing space.
The expansion includes multiple 3,000L solid-phase and liquid-phase peptide synthesis (SPPS and LPPS) lines, cleavage lines up to 2,000L, and deprotection lines up to 1,000L. These upgrades will enable the company to support GMP operations for batch sizes ranging from 50 to 100 kilogrammes.
The facility has been designed to accommodate both conventional synthesis and fragment-based hybrid synthesis, reflecting rising demand for large-scale peptide active pharmaceutical ingredient (API) manufacturing.
According to the company, the investment aims to provide customers with increased flexibility, scalability, and faster project delivery, while maintaining high standards of quality.
